Core Insights - Alterity Therapeutics has received positive regulatory feedback from the FDA regarding its Phase 3 development program for ATH434 in Multiple System Atrophy (MSA) [1][2] - The Type C Meeting with the FDA confirmed alignment on clinical pharmacology and non-clinical development elements, which is crucial for initiating the Phase 3 pivotal trial [2][3] - The company aims to achieve agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting scheduled for mid-2026 [3] Company Overview - Alterity Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [4] - The lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial and positive results in an open-label Phase 2 trial for advanced MSA [4] - The company operates from Melbourne, Australia, and San Francisco, California, and has a drug discovery platform aimed at creating patentable compounds for neurological diseases [4]

Summary of Alterity Therapeutics Conference Call Company Overview - **Company**: Alterity Therapeutics (NasdaqCM:ATHE) - **Focus**: Development of therapies for neurodegenerative diseases, specifically targeting multiple system atrophy (MSA) and potentially Parkinson's disease [1][2] Industry Context - **Disease**: Multiple System Atrophy (MSA) - **Market Potential**: Estimated worldwide sales of $2.4 billion due to lack of approved treatments targeting the disease pathology [2][27] - **Patient Demographics**: Approximately 50,000 patients in the U.S. with MSA, characterized by rapid disease progression [4][6] Core Product Insights - **Lead Candidate**: ATH434 - **Phase II Results**: Demonstrated a treatment effect of up to 48% on functional endpoints in MSA patients [2][19] - **Administration**: Orally administered, preferred over intravenous or direct brain injection methods [2][11] - **Mechanism of Action**: Targets iron accumulation and alpha-synuclein aggregation in neurons, aiming to preserve neuronal function [8][10][11] Clinical Development - **Current Status**: Completed Phase II, preparing for Phase III trials [3][27] - **Key Study Design**: Randomized double-blind placebo-controlled study with 77 patients, assessing various endpoints including the modified UMSARS Part One [13][14] - **Clinical Results**: - Placebo group showed an 8-point increase in MSA rating scale, while both treatment groups showed significant reductions in decline [19] - No serious adverse events related to the drug were reported [22] Future Milestones - **Upcoming Events**: - Targeting an end-of-phase II meeting with the FDA by mid-year to discuss Phase III design [31] - Anticipated initiation of Phase III study approximately six months post-FDA meeting [31] - **Expansion Plans**: Potential to explore additional indications such as Parkinson's disease and other orphan diseases [12][35] Commercial Assessment - **Neurologist Feedback**: Over 70% of surveyed neurologists expressed strong intent to prescribe ATH434, highlighting the unmet need in treating MSA [26] - **Sales Projections**: Peak sales estimated at $2.4 billion, reinforcing the commercial viability of ATH434 [27][39] Additional Considerations - **Research Collaborations**: Ongoing collaboration with the Michael J. Fox Foundation for research in Parkinson's disease [4] - **Regulatory Designations**: ATH434 has orphan drug designation in the U.S. and EU, along with fast track designation from the FDA [12] Conclusion - **Strategic Positioning**: Alterity Therapeutics is well-positioned to advance ATH434 through clinical trials, with significant market potential and a strong focus on addressing critical unmet needs in neurodegenerative diseases [27][39]

Core Insights - Alterity Therapeutics has appointed Dr. Daniel O. Claassen as Chief Medical Advisor, effective March 2026, bringing extensive expertise in neurodegenerative diseases to the company [1][3] Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) [4] - The company is preparing to initiate a Phase 3 pivotal trial for its lead asset, ATH434, which has shown clinically meaningful efficacy in Phase 2 trials [4] Dr. Claassen's Background - Dr. Claassen is a board-certified neurologist with over 20 years of experience in clinical and translational research related to movement disorders and cognitive neurology [2] - He has authored hundreds of peer-reviewed publications and has been a principal investigator in numerous clinical trials, contributing significantly to the advancement of therapies for neurodegenerative disorders [2] Strategic Importance - The appointment of Dr. Claassen is seen as pivotal for Alterity as it advances ATH434 into Phase 3 trials, with his previous involvement in the Phase 2 study enhancing his qualifications to guide the company's growth [3] - Dr. Claassen's focus on translating academic research into clinical applications aligns with the urgent need for disease-modifying therapies in neurodegenerative diseases [3]

Core Viewpoint - Alterity Therapeutics is advancing ATH434 in late-stage clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies [1][3] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [1][10] - The company is preparing to initiate a Phase 3 pivotal trial in MSA, having demonstrated clinically meaningful efficacy in a Phase 2 clinical trial [10] Disease Background - MSA is characterized by motor impairment, autonomic dysfunction, and rapid loss of independence, with symptoms resembling Parkinson's disease, making early diagnosis challenging [2][9] - The disease affects up to 50,000 individuals in the U.S., and there are currently no approved drugs to slow its progression or cure it [9] Clinical Development of ATH434 - ATH434 is an investigational oral therapy designed to redistribute excess iron in the brain, which contributes to neurodegeneration in MSA [3][6] - Positive results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial showed robust clinical efficacy and a favorable safety profile [6][8] - The Phase 2 trial enrolled 77 adults and demonstrated significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I compared to placebo [8] Research and Biomarkers - The clinical program incorporates biomarkers and advanced neuroimaging to better characterize disease progression and assess therapeutic impact [4] - Biomarkers indicated that both dose levels of ATH434 reduced iron accumulation in MSA-affected brain regions and showed trends in preserving brain volume [8] Awareness and Advocacy - Throughout MSA Awareness Month, the company will share educational information and highlight the experiences of the MSA community, emphasizing the need for continued research [5]

Core Viewpoint - Alterity Therapeutics is advancing its ATH434 program for Multiple System Atrophy (MSA), with strengthened Phase 2 data and a solid cash position, while preparing for a pivotal Phase 3 clinical trial and engaging with the FDA [2][3][7]. Phase 2 Clinical Program & Regulatory Progress - The company has made significant progress in its Phase 2 trial for ATH434, with new analyses enhancing confidence in its potential as a disease-modifying therapy for MSA, projecting a commercial opportunity of US$2.4 billion [3][4]. - Preparations for an End-of-Phase 2 meeting with the FDA are underway, aimed at aligning on the design and requirements for a pivotal Phase 3 trial [5][9]. - A new analysis from the Phase 2 trial showed an improved efficacy signal in the 75 mg dose group, with a relative treatment effect increase from 30% to 35% compared to placebo [6]. Cash Position - As of December 31, 2025, the company reported a cash balance of A$49.2 million, with operating cash outflows of A$5.28 million for the quarter, providing a solid runway for regulatory and clinical objectives [21]. Corporate and Financial Update - The governance and leadership structure has been strengthened to support the transition into late-stage development, with key appointments made to enhance strategic execution [15][20]. - The company is exploring non-dilutive funding pathways for Phase 3 development through ongoing discussions with pharmaceutical partners [7][14]. Scientific and Clinical Engagement - Alterity has actively engaged with the global neurology community through scientific presentations, which are crucial for disseminating clinical data and refining interpretations of Phase 2 results [11][12]. - A Clinical Advisory Board meeting was held to review Phase 2 data and provide expert input for the Phase 3 trial design [12]. Outlook - The company is focused on advancing ATH434 toward a pivotal Phase 3 program, ensuring regulatory alignment with the FDA, and pursuing strategic partnerships to maximize long-term shareholder value [23].

Core Insights - Alterity Therapeutics has successfully completed its Phase 2 program for ATH434 in multiple system atrophy (MSA), demonstrating safety and efficacy, and is now preparing for Phase 3 trials [1][2][5] Company Developments - The Phase 2 trials showed ATH434 to be safe and well-tolerated, with significant efficacy signals in a market with no current disease-modifying treatments, representing a potential $2.4 billion opportunity [2][5] - The company is focused on advancing ATH434 towards a pivotal Phase 3 clinical program and is set to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize trial design [8][14] - Alterity has strengthened its leadership team, appointing Julian Babarczy as Chair of the Board and enhancing its governance structure to support growth [12][13] Clinical and Scientific Progress - ATH434 has shown promising results in slowing disease progression across various clinical endpoints, including functional measures and symptoms of orthostatic hypotension [5][11] - The company has deepened its understanding of MSA biology through biomarker and imaging studies, reinforcing the role of dysregulated brain iron and α-synuclein pathology [6][7] Future Objectives - The company aims to finalize its regulatory strategy for the Phase 3 trial, deepen engagement with the medical community, and build for scalable growth, including expanding intellectual property protection [18]

Core Insights - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson's disease and related disorders [2][4] - The company will present a corporate update at the Bell Potter Healthcare Conference on November 19, 2025, for Australian participants and November 18, 2025, for U.S. participants [1][2] - Alterity's lead asset, ATH434, has shown clinically meaningful efficacy in a Phase 2 clinical trial for Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder [2] Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company based in Melbourne, Australia, and San Francisco, California, dedicated to creating treatments for neurodegenerative diseases [2] - The company has a drug discovery platform that generates patentable chemical compounds aimed at treating the underlying pathology of neurological diseases [2] Clinical Development - ATH434 has recently reported positive data from an open-label Phase 2 clinical trial in advanced MSA, indicating progress in the company's drug development program [2] - The company is committed to developing therapies that can modify the course of neurodegenerative diseases, with a specific focus on Parkinson's disease [2]

Core Insights - Alterity Therapeutics announced promising results from the ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA), highlighting the drug's potential to impact treatment and disease progression significantly [1][2] Group 1: Clinical Trial Results - The ATH434-201 trial was a randomized, double-blind, placebo-controlled study involving 77 adults, assessing the efficacy, safety, and pharmacokinetics of ATH434 over 12 months [8] - Severe orthostatic hypotension (OH) was observed in 29.2% of participants in the 75 mg dose group, compared to 4% in the 50 mg group and 4.5% in the placebo group, indicating a significant baseline difference [4] - The efficacy signal in the 75 mg dose group improved from -2.4 to -2.8 points when controlling for OH, enhancing the relative treatment effect from 30% to 35% [4] Group 2: Efficacy and Safety - ATH434 demonstrated stability in OH symptoms across both dose groups, while placebo patients worsened by approximately 6 points over 52 weeks [5] - The drug showed clinically and statistically significant improvements on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, indicating its potential effectiveness in managing MSA symptoms [8] - ATH434 was well tolerated, with adverse event rates similar to placebo and no serious adverse events attributed to the drug [8] Group 3: Future Development - The company is actively planning Phase 3 trials and preparing for interactions with the FDA, aiming to bring a meaningful treatment option to MSA patients [2][7] - ATH434 has received Fast Track Designation and Orphan Drug Designation from the FDA and the European Commission, underscoring its potential as a treatment for MSA [7] Group 4: Background on MSA - Multiple System Atrophy (MSA) is a rare neurodegenerative disease affecting up to 50,000 individuals in the U.S., characterized by autonomic dysfunction and rapid disease progression [9] - Currently, there are no approved drugs that can slow the progression of MSA, highlighting the need for effective treatments like ATH434 [9] Group 5: Company Overview - Alterity Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases, with ATH434 as its lead candidate showing promising clinical efficacy [10] - The company is based in Melbourne, Australia, and San Francisco, California, and is dedicated to creating innovative treatments for patients with neurodegenerative conditions [10]

Core Insights - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) [2][16] - The company reported positive clinical results for its lead asset, ATH434, and highlighted a potential market opportunity of approximately USD 2.4 billion for MSA treatments [4][13] Financial Overview - As of September 30, 2025, Alterity's cash position was A$54.56 million, with operating cash outflows of A$5.34 million for the quarter [5][9] - The company raised A$20 million in gross proceeds from a strategic placement to advance its programs [14] Clinical Development - Positive results from the ATH434-201 Phase 2 clinical trial showed a relative treatment effect of 35% in the 75 mg dose group at 52 weeks [8][10] - The ATH434-202 open-label trial demonstrated comparable efficacy to earlier-stage patients, confirming ATH434's favorable profile [10][16] - The company is engaging with the U.S. FDA to discuss data required for Phase 3 trials, with an End-of-Phase 2 meeting expected in mid-2026 [7][4] Regulatory and Market Engagement - ATH434 has received Fast Track Designation from the FDA, allowing for a series of Type C meetings to discuss necessary data for Phase 3 [6][7] - An independent commercial assessment indicated strong physician interest in ATH434, with over 70% of surveyed neurologists likely to prescribe it based on Phase 2 data [13] Research and Innovation - The company published findings from the bioMUSE Natural History Study, introducing the MSA Atrophy Index as a potential diagnostic tool for MSA [11] - Ongoing presentations at major conferences highlight the clinical progress and potential of ATH434 in treating MSA [12][16]

Core Insights - Alterity Therapeutics announced positive results from the ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA), demonstrating that ATH434 slows disease progression and stabilizes orthostatic hypotension [1][2] Group 1: Clinical Trial Results - The ATH434-201 trial involved 77 participants, comparing two doses of ATH434 (50 mg and 75 mg) against a placebo, with results indicating a 48% relative treatment effect at the 50 mg dose and a 30% effect at the 75 mg dose on the UMSARS I scale at 52 weeks [3][13] - A new analysis accounting for baseline differences in orthostatic hypotension (OH) showed a strengthened efficacy signal in the 75 mg group, with a relative treatment effect of 35% [5][13] - ATH434 demonstrated a beneficial effect on OH symptoms, with placebo patients worsening significantly while both treatment groups remained stable [5][7] Group 2: Neuroimaging and Biomarkers - The trial utilized advanced neuroimaging and biomarkers to refine MSA diagnosis and track disease evolution, showing that ATH434 reduced iron accumulation in affected brain regions [7][8] - Imaging biomarkers supported MSA diagnosis in 96.1% of participants, indicating a multimodal approach may enhance diagnostic accuracy [8][9] Group 3: Safety and Tolerability - ATH434 was well tolerated, with adverse event rates similar to placebo and no serious adverse events attributed to the drug [7][13] - The study also indicated increased outpatient activity levels in participants treated with ATH434, as measured by wearable sensors [7][13] Group 4: Company Overview - Alterity Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases, with ATH434 being a lead candidate showing robust clinical efficacy in MSA [11][15] - The company has received Fast Track Designation and Orphan Drug Designation from the FDA for ATH434, highlighting its potential in treating MSA [11][15]